Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison J Moskowitz

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Journal of the American Academy of Dermatology|April 8, 2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndromeAmrita Goyal, Daniel O'Leary, Bouthaina Dabaja, et al.
Transplantation and Cellular Therapy|September 2, 2024
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary SyndromeAmrita Goyal, Daniel O'Leary, Bouthaina Dabaja, et al.
Blood|December 10, 2025
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosisJoseph M Rocco, Joseph H Oved, Rikita J Patel, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyMichael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Journal of the American Academy of Dermatology|April 8, 2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndromeAmrita Goyal, Daniel O'Leary, Bouthaina Dabaja, et al.
Transplantation and Cellular Therapy|September 2, 2024
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary SyndromeAmrita Goyal, Daniel O'Leary, Bouthaina Dabaja, et al.
Blood|December 10, 2025
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosisJoseph M Rocco, Joseph H Oved, Rikita J Patel, et al.
Pageof 10